This inventor holds 1 USPTO granted patent. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Innovations of Jean-Charles Cerrotini
Introduction
Jean-Charles Cerrotini is a notable inventor based in Lausanne, Switzerland. He has made significant contributions to the field of cancer research, particularly through his innovative work on peptide derivatives. His research focuses on enhancing immune responses against cancer cells.
Latest Patents
Jean-Charles Cerrotini holds a patent for "NY-ESO-1-peptide derivatives, and uses thereof." This invention relates to variant peptides that bind to HLA molecules, leading to the lysis of cells via cytolytic T cell lines. The variants are based on NY-ESO-1 peptides, which can be incorporated into immune tetramers, serving as useful T cell sorters. He has 1 patent to his name.
Career Highlights
Cerrotini is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in immunology and cancer treatment. His work has the potential to significantly impact therapeutic strategies for cancer patients.
Collaborations
Some of his notable coworkers include Danila Valmori and Pedro Romero, who collaborate with him in various research initiatives.
Conclusion
Jean-Charles Cerrotini's innovative work in peptide derivatives showcases his commitment to advancing cancer research. His contributions are paving the way for new therapeutic approaches in immunology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile